CD19 and neoplasm: The lack of CD19 surface expression may be due to mutations or alternative splicing events (86, 87), suggesting the possibility that in some patients the CD19 protein may be truncated, therefore lacking the epitope that is necessary to trigger recognition and killing of tumor cells by CAR T cells and CD19 detection by flow cytometry (88).